Back to articles

First FDA-approved treatment for patients with binge-eating disorder


FDA expanded the use of lisdexamfetamine (Vyvanse—Shire) for the treatment of adults with moderate to severe binge-eating disorder after data from three clinical studies showed that patients taking the drug had a decrease in the number of binge-eating days per week and fewer obsessive–compulsive binge-eating behaviors compared with those given placebo.